Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

NCT04973306 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

176

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma Stage II
Esophageal Squamous Cell Carcinoma Stage III

Interventions

PROCEDURE: Neoadjuvant Chemoradiotherapy
DRUG: Tislelizumab
PROCEDURE: Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]